12-羥基伊波加明

**12-羥基伊波加明**
臨床資料
其他名稱	12-Hydroxyibogamine; Ibogamin-12-ol; O-desmethylibogaine; (-)-Noribogaine;
法律規範狀態
法律規範	澳：限醫生處方（S4）; 美：未列入管制 (but still a Schedule I analogue due to being a main metabolite of C-I ibogaine);
識別資訊
	IUPAC命名法 (1R,15R,17S,18S)-17-ethyl-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraen-7-ol; ;
CAS號	481-88-9
PubChem CID	3083548;
ChemSpider	2340735 ;
UNII	87T5QTN9SK;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID90963998 ;
化學資訊
化學式	C19H24N2O
摩爾質量	296.41 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES CC[C@H]1C[C@@H]2C[C@@H]3[C@H]1N(C2)CCC4=C3NC5=C4C=C(C=C5)O;
	InChI InChI=1S/C19H24N2O/c1-2-12-7-11-8-16-18-14(5-6-21(10-11)19(12)16)15-9-13(22)3-4-17(15)20-18/h3-4,9,11-12,16,19-20,22H,2,5-8,10H2,1H3/t11-,12+,16+,19+/m1/s1 ; Key:RAUCDOKTMDOIPF-RYRUWHOVSA-N ;

12-羥基伊波加明（英語：12-hydroxyibogamine，或稱為：去甲伊博格鹼，Noribogaine）是一種含氮有機化合物，化學式C₁₉H₂₄N₂O，是生物鹼類精神活性藥物伊波加因的代謝產物。^[1]^[2]^[3]^[4]

參考文獻

^ Mash DC, Ameer B, Prou D, Howes JF, Maillet EL. Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents. J. Psychopharmacol. (Oxford). 2016, 30 (7): 688–97. PMID 27044509. S2CID 40776971. doi:10.1177/0269881116641331.
^ Glick SD, Maisonneuve IS. Mechanisms of antiaddictive actions of ibogaine. Annals of the New York Academy of Sciences. May 1998, 844 (1): 214–26. Bibcode:1998NYASA.844..214G. PMID 9668680. S2CID 11416176. doi:10.1111/j.1749-6632.1998.tb08237.x.
^ Baumann MH, Pablo J, Ali SF, Rothman RB, Mash DC. Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite, noribogaine. The Alkaloids: Chemistry and Biology. 2001, 56: 79–113. PMID 11705118. doi:10.1016/S0099-9598(01)56009-5.
^ Kubiliene A, Marksiene R, Kazlauskas S, Sadauskiene I, Razukas A, Ivanov L. Acute toxicity of ibogaine and noribogaine. Medicina. 2008, 44 (12): 984–8. PMID 19142057. doi:10.3390/medicina44120123 .